NCT04374279

Trial to Promote Recovery From COVID-19 With Endocrine Therapy

A Phase II Trial to Promote Recovery From COVID-19 With Endocrine Therapy

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with COVID-19 requiring inpatient hospitalization will be randomized to treatment with standard of care or standard of care + bicalutamide. This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.

Conditions

• COVID-19
• SARS-CoV 2

Interventions

Type	Name	Description
DRUG	Bicalutamide 150 Mg Oral Tablet	Bicalutamide 150 mg by mouth daily for 7 days

Timeline

• Start date: 2021-04-01
• Primary completion: 2022-01-01
• Completion: 2022-01-01
• First posted: 2020-05-05
• Last updated: 2021-03-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study